Use of renin-angiotensin-aldosterone system blockade in controversial chronic kidney disease populations

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Renin-angiotensin-aldosterone system (RAAS) blockers are primary treatments for hypertension in chronic kidney disease (CKD).
• They effectively manage blood pressure, proteinuria, slow CKD progression, and reduce cardiovascular risk.
• Recent studies raise questions about their efficacy and safety in specific patient subgroups.

Purpose of the Study:

• To review existing data on RAAS blocker use in controversial CKD populations.
• To identify areas for future research regarding RAAS blockers in specific patient groups.

Main Methods:

• Systematic review of published literature.
• Analysis of randomized clinical trials and observational studies.
• Focus on patient subgroups with debated RAAS blocker benefits.

Main Results:

• RAAS blockers are generally beneficial but evidence is controversial in advanced CKD.
• Their use in non-proteinuric nephropathies and elderly patients warrants further investigation.
• Adverse event susceptibility in certain groups needs consideration.

Conclusions:

• RAAS blockers remain crucial for CKD hypertension management.
• Further research is needed to clarify optimal use in controversial populations.
• Personalized treatment strategies may be required for specific CKD patient subgroups.